Floatz logo

IOFLUPANE

Multiple System Atrophy (MSA)

GE HealthcareSmall moleculePhase 3Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

27 Active assets in the Multiple System Atrophy (MSA) cohort.

Asset / SponsorPhaseRating
Droxidopa
Loma Linda University
Phase 3BB
Zoledronate
California Pacific Medical Center Research Institute
Phase 4BB
ATH-434
Alterity Therapeutics
Phase 2B
Riluzole
King's College London
Phase 3B
Exidavnemab
BioArctic AB
Phase 2CCC

View all 40 →

Same molecule, other indications

IOFLUPANE is also rated in:

REM sleep behavior disorderDormant
BBB
Indicative ·
72 / 100
View asset →
progressive supranuclear palsyDormant
BB
Indicative ·
69 / 100
View asset →
dementiaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →